Inflammatory breast cancer: features and outcomes in a breast unit in Dakar, Senegal

Authors

  • Mamour Gueye Gynecologic and Obstetric Clinic, Aristide Le Dantec Teaching Hospital, PO BOX 3001, Pasteur Avenue, Cheikh Anta Diop University, Dakar, Senegal
  • Serigne Modou Kane-Gueye Gynecologic and Obstetric Clinic, Aristide Le Dantec Teaching Hospital, PO BOX 3001, Pasteur Avenue, Cheikh Anta Diop University, Dakar, Senegal
  • Mame Diarra Ndiaye-Gueye Gynecologic and Obstetric Clinic, Aristide Le Dantec Teaching Hospital, PO BOX 3001, Pasteur Avenue, Cheikh Anta Diop University, Dakar, Senegal
  • Omar Gassama Gynecologic and Obstetric Clinic, Aristide Le Dantec Teaching Hospital, PO BOX 3001, Pasteur Avenue, Cheikh Anta Diop University, Dakar, Senegal
  • Moussa Diallo Gynecologic and Obstetric Clinic, Aristide Le Dantec Teaching Hospital, PO BOX 3001, Pasteur Avenue, Cheikh Anta Diop University, Dakar, Senegal
  • Jean Charles Moreau Gynecologic and Obstetric Clinic, Aristide Le Dantec Teaching Hospital, PO BOX 3001, Pasteur Avenue, Cheikh Anta Diop University, Dakar, Senegal

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20160370

Keywords:

Inflammatory breast cancer, Outcome, Senegal

Abstract

Background: The aim of this study was to determine clinical features and outcomes of patients with inflammatory breast cancer (IBC) treated in our breast unit.

Methods: This study was performed at Gynaecologic and Obstetric Clinic of Dakar Teaching Hospital, in which a breast unit was created since 2007. All women with diagnosis of inflammatory breast cancer in our Breast Unit between January 2010 and December 2013 were included in this study. The diagnosis of IBC was made clinically using the American Joint Committee on Cancer (AJCC) and confirmed histologically. The follow-up cut-off for this data set was December 31st, 2014. All analyses for this study were performed using SPSS software (version 20.0).

Results: Between 2010 and 2013, 22 women with breast cancer who met eligibility criteria were included out of 161 patients followed for breast cancer leading to a frequency of 13.6%. The median age at diagnosis was 43.4 years (26-79 years). Mean time to diagnosis was 4 months. The mean time to recurrence was 11.2 months. This recurrence was observed in 45.5% of cases. The median overall survival was 13.3 months (CI 95% 8.576-18.526), the survival rate was 31.8%.

Conclusions: This series shows a high frequency of inflammatory breast cancer. These tumours are very aggressive with a very poor prognosis.

References

Sobin LH, Compton CC. TNM seventh edition: what’s new, what’schanged: communication from the International Union Against Cancer and the American Joint Committee on Cancer Cancer. 2010;116:5336-9.

Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966-75.

Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;22:9-23.

van Uden DJP, van Laarhoven HWM, Westenberg AH, d Wilty JHW, Blanken-Peeters CFJM. Inflammatory breast cancer: an overview. Crit Rev Oncol Hematol. 2015;93:116-26.

American Joint Committee on Cancer. Breast. In: AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven; 1997:171.

Bell CA. A system of operative surgery. Hartford, CT: Hale and Hosmer; 1814:136.

Lee BJ, Tannenbaum NE. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of the Memorial Hospital. Surg Gynecol Obstet. 1924;39:580-95.

Cariati M, Bennett-Britton TM, Pinder SE, Purushotham AD. Inflammatory breast cancer. Surg Oncol. 2005;14:133-43.

Wingo PA, Jamison PM, Young JL, Gargiullo P. Population based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Cause Control. 2004;15(3):321-8.

Haagensen CD. Diseases of the female breast. Trans N Engl Obstet Gynecol Soc. 1956;10:141-56.

Rea D, Francis A, Hanby AM, Speirs V, Rakha A, Shaaban A et al. Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. British J Cancer. 2015;112:1613-5.

Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am J Cancer. 1938;33:33.

Serin D, Escoute M, Berger C. Traitement locorégional. La radiochimiothérapie concomitante : une solution d’avenir pour un meilleur contrôle local? In: Société française de sénologie et de pathologie mammaire. Le sein inflammatoire. Toulouse:Arnette; 2000:91-97.

Stalsberg H, Awuah B, Ibarra JA, Nsiah-Asare A. Re-establishing a surgical pathology service in Kumasi, Ghana: case report and discussion of barriers and key elements of a successful collaboration between low- and high-resource countries. Cancer. 2008;113:2338-46.

Sohani AR, Sohani MA. Static digital telepathology: a model for diagnostic and educational support to pathologists in the developing world. Anal Cell Pathol. 2012;35:25-30.

Tabbane F, Muenz L, Jaziri M, Cammoun M, Belhassen S, Mourali N. Clinical and prognostic features of a rapidly progressing breast cancer in Tunisia. Cancer. 1977;40(1):376-83.

Downloads

Published

2016-12-17

Issue

Section

Original Research Articles